This is a Delivery Order under the $3,500.00 Diagnostic Pre-Clinical Services Program IDIQ contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp that provides biopharmaceutical research, development, manufacturing, and testing services. This Delivery Order supports the development of candidate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,500 firm fixed price delivery order contract to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, for the Diagnostic Pre-Clinical Services Program. This contract is part of a larger Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle that provides funding for development processes needed to bring candidate infectious disease diagnostics to market. Dynport has previous experience...
This is a delivery order awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases. The $129,670.00 award is part of the Therapeutics Against Infectious Diseases Phase 1 contract vehicle, a multi-year indefinite delivery, indefinite quantity (IDIQ) contract that funds early-stage clinical trials of candidate therapeutics and vaccines. The...
This federal contract award to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp, is in support of a Phase 1 Clinical Trial Unit for Therapeutics Against Infectious Diseases. The $1,757,807.36 ceiling value contract was awarded on August 19, 2016 by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services. The contract is a delivery order against the $30 million Preclinical Services for Biopharmaceutical...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corp. The $222,661 award is a delivery order under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase 1 clinical trials for therapeutics against infectious diseases. The contract does not have a set-aside designation. This order is for Dynport to conduct Phase 1...
This is a cost-plus-fixed-fee delivery order awarded to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The $2,191,163 task order is part of the $346 million Early Phase Clinical Trial Units (EPCTU) indefinite-delivery, indefinite-quantity (IDIQ) contract, which funds Phase I clinical trial services. Dynport, a provider of research, development,...
This is a delivery order under the "Therapeutics Against Infectious Diseases Phase 1" indefinite delivery, indefinite quantity (IDIQ) contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The order, valued at $5,167,891.00, funds a Phase 1 clinical trial unit for therapeutic candidates against infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General...
This is a delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $4,120,677 cost-plus-fixed-fee contract is for a Phase 1 clinical trial unit to support the development of therapeutics against infectious diseases. This award is part of the larger Therapeutics Against Infectious Diseases Phase 1 contract vehicle....
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1.2 million delivery order contract to Dynport Vaccine Company LLC DVC Segment Division for the evaluation of cell lines producing a monoclonal antibody, and production and characterization of a cGMP master cell bank. Dynport Vaccine Company LLC DVC Segment Division, a subsidiary of General Dynamics Corp., will perform this work under its Preclinical Services...
This is a cost-plus-fixed-fee delivery order awarded by the Medical Command (MEDCOM) of the U.S. Army to Dynport Vaccine Company LLC, a subsidiary of General Dynamics Corporation. The $1,685,156.08 contract is for the Phase 2 clinical trial of the Comprehensive Preventive and Preparedness (CPP) program, which develops medical countermeasures for infectious diseases. The contract is part of Dynport's existing $30 million Preclinical Services for Biopharmaceutical Product Development indefinite...